Mechanical Circulatory Support in Refractory Cardiogenic Shock: Bridging to Recovery or Transplant

Background: Refractory cardiogenic shock remains one of the most challenging conditions in contemporary critical care, with high mortality despite advances in pharmacological therapy, revascularization, and intensive hemodynamic management. Mechanical circulatory support (MCS) has emerged as a critical strategy for patients with persistent tissue hypoperfusion and inadequate cardiac output despite optimal conventional treatment. Beyond short-term hemodynamic stabilization, MCS may serve as a bridge to myocardial recovery, durable ventricular assist device implantation, or heart transplantation. Methods: This review examines the current role of temporary and durable MCS in refractory cardiogenic shock, focusing on patient selection, timing of initiation, device selection, hemodynamic optimization, complications, and strategies for transition toward recovery or definitive advanced heart failure therapies. Particular attention is given to intra-aortic balloon pump, Impella, venoarterial extracorporeal membrane oxygenation, and durable ventricular assist devices. Results: Early recognition of refractory shock and appropriate patient selection are fundamental to achieving favorable outcomes with MCS. Temporary devices can rapidly restore systemic perfusion, reduce ventricular loading, and provide time for myocardial recovery or evaluation for advanced therapies. However, delayed initiation, severe multiorgan dysfunction, irreversible neurological injury, and inappropriate patient selection are associated with poor outcomes. A structured approach incorporating hemodynamic assessment, metabolic markers, echocardiography, end-organ function, and response to support may facilitate individualized escalation or de-escalation. In selected patients, MCS can successfully provide a bridge to recovery, bridge to durable ventricular assist device implantation, or bridge to transplantation. Conclusion: MCS represents a cornerstone of contemporary management for carefully selected patients with refractory cardiogenic shock. Its greatest value may extend beyond immediate survival by creating a therapeutic window for myocardial recovery or definitive advanced heart failure therapy. Future strategies integrating precision phenotyping, early multidisciplinary intervention, and increasingly sophisticated unloading and support technologies may further improve outcomes.